Pfizer Spain Highlights Innovation and Impact in 2024 Report Amid Key Anniversaries

Pfizer Spain presents its 2024 Impact Report, a document that captures the company’s key advances in the fields of healthcare, science, innovation , and social commitment. This is a particularly significant year, marked by the celebration of Pfizer’s 175th anniversary globally and the 25th anniversary of the Pfizer Foundation in Spain.

In this context, the company has reaffirmed its commitment to offering innovations that change patients ‘ lives, acting responsibly and committed to the sustainable use of resources so as not to compromise the future.

Celebrating 175 years globally and 25 years of its foundation in Spain, Pfizer underscores advances in research, healthcare innovation, and social commitment through its 2024 Impact Report

“This report is a tangible example of Pfizer’s commitment to people’s health and the progress of society. We have spent 175 years transforming scientific innovation into real solutions for patients, and this report firmly reflects our daily work, always putting the patient at the center and maintaining our commitment to health, research, and society as a whole,” said Carlos Murillo, President of Pfizer Spain.

Pfizer Spain has consolidated its position as a benchmark in clinical research, leading the group’s number of research projects outside the US. By 2024, it had collaborated with 839 research centers across the country and conducted 113 clinical trials in 13 different therapeutic areas, including Oncology , Rare Diseases , Inflammation and Immunology , and Neurology . Furthermore, the company has invested €54 million in R&D (as of 2023), reaffirming its position as one of the key players in the biopharmaceutical sector in Spain and reflecting its commitment to scientific advancement and improving global health.

Over the past year, the company has made four new treatments available to healthcare professionals and patients, representing significant advances in key areas such as oncology, immunology, neurology, and vaccines. These innovations significantly contribute to improving the quality of life of people affected by conditions such as multiple myeloma, alopecia areata, migraines , and respiratory syncytial virus (RSV).

For the fifth consecutive year, Pfizer Spain has renewed its Top Employer seal, achieving a score of 91.89%, which demonstrates its firm commitment to the well-being, equality and professional development of its 1,145 employees, with a balanced representation of women (58%) and men (42%).

Pfizer has also collaborated with more than 60 patient organizations, supporting nearly 70 initiatives aimed at raising awareness, training, and improving access to treatments. These initiatives range from awareness campaigns and informational events to direct support projects and training for patients and caregivers, with a special focus on areas such as oncology, rare diseases, mental health , and immunology.

Among Pfizer Spain’s notable initiatives are programs focused on breast cancer, such as “More Life for Your Life,” which provides emotional support and raises awareness of the disease, and “Beyond the Mirror,” a comprehensive guide with dermo-aesthetic recommendations for healthcare professionals and patients. In the area of ​​rare diseases, the “Las Raras” campaign toured Malaga, Valencia , and Santander with a Fashion Road Show. In addition, the company has promoted scientific meetings in various therapeutic areas and strengthened its support for patient associations.

At the same time, Pfizer Spain has continued to strengthen strategic alliances with key organizations to foster innovation and sustainable development. These include collaborations with organizations such as the Cotec Foundation, Multinacionales por España, Farmaindustria , the SERES Foundation, and the U.S. Chamber of Commerce in Spain (Amcham Spain). These alliances allow for the sharing of best practices, the promotion of joint initiatives, and the consolidation of the company’s commitment to the well-being of society from a collaborative and transformative perspective.

Likewise, through the Pfizer Foundation, the company has promoted scientific innovation and entrepreneurship in health through initiatives such as the Scientific Innovation Awards for Young Researchers, the ‘Health Guardians 2030’ educational program in schools, and support for health entrepreneurship through Innomakers4Health and e-Dea Salud.

__

(Featured image by mike_ramirez_mx via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us